WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Rural Entrepreneur Helps Farmers Live Better LivesDancer Sheds Light on Living with a Hearing DisabilityXinjiang Story: Uygur Dancer Blends Folk Elegance with Modern Street BeatsYoung Entrepreneur Develops Persimmon Businesses, Helps Rural Women Increase IncomesModernization, Mechanization Make Farmer's Life a BreezeRetired Principal Promotes 'Red Spirit' via ReadingMy Olympic Winter Games Story: The Dream That Keeps Me GoingSwiatek beats Gauff to reach China Open finalXie Ai'e: Always Thinking About PeopleProfile: Wheelchair